Advertisement

Topics

SkinBioTherapeutics to reveal data from human safety study in coming weeks

10:57 EDT 25 Oct 2018 | Proactive Investors

Dr Cath O'Neil, chief executive of SkinBioTherapeutics PLC (LON:SBTX), updates Proactive London's Andrew Scott on the human cosmetic studies of their technology which have now kicked off.

SkinBio began first-in-human studies last month, with researchers assessing skin irritancy, moisturisation potential and skin barrier function of different concentrations of the cream.

Results from the first two trials – irritancy and moisturisation – are due in the coming weeks, although data from the skin barrier study won’t be ready until the first quarter of 2019.

Original Article: SkinBioTherapeutics to reveal data from human safety study in coming weeks

NEXT ARTICLE

More From BioPortfolio on "SkinBioTherapeutics to reveal data from human safety study in coming weeks"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...